Durham, NC (PRWEB) August 11, 2015
Bright Wolf, LLC, a leading Internet of Things (IoT) platform provider, is pleased to announce Haemonetics Corporation (NYSE: HAE), a global healthcare company dedicated to providing innovative blood management solutions, as a new production client. Haemonetics worked with Bright Wolf to develop the HaemoCloud and HaemoCommunicator products, both recipients of the 2015 IoT Evolution Product of the Year Award. Central to Haemonetics strategy, these products were designed to connect all Haemonetics devices and software, creating unprecedented control of the blood value chain.
Haemonetics evaluated IoT platform providers in 2014 and selected Bright Wolf based on the company’s technical prowess, platform characteristics and design philosophy. “We have a vision for Connected Blood, transforming the practice of blood management by capturing and analyzing real-time device and procedure data and integrating with the greater healthcare ecosystem. Beyond their deep experience with connected systems, Bright Wolf fundamentally differentiated themselves technically by architecting a system that gracefully enables our increasing needs for edge-based intelligence,” said Walter Hauck, VP, Worldwide Product Development.
In a June 2015 report, McKinsey & Company estimated the potential impact the Internet of Things, when used to improve healthcare, could range from $170B to $1.7T a year by 2025.
HaemoCommunicator works within an institution to format and transfer data from diagnostic (thromboelastography, i.e., TEG® 6s) and cell salvage devices (i.e., Cell Saver® Elite®). Operational data from the device is also managed by HaemoCommunicator to provide lab and IT staff real-time access to device performance. Each HaemoCommunicator installation compiles device performance data and transfers it to HaemoCloud allowing Haemonetics’ customers and support organizations to monitor the use and performance of each device. HaemoCommunicator is designed to integrate Haemonetics and devices and software, to create a seamless data experience for customers. Over time, data collected in HaemoCloud will allow Haemonetics to build preventative maintenance algorithms and offer industry-leading device performance for our customers.
“It took one meeting with Haemonetics to appreciate the gravity of its strategy and how we could be part of driving change to the healthcare industry through improved patient care and reduction of costs. We knew our edge-to-enterprise platform was uniquely positioned to provide the foundation for Haemoentics’ distributed intelligence and global regulatory compliance requirements,” said David Houghton, Director at Bright Wolf.
“Many decisions need to be made, when companies are transforming their businesses through IoT, with platform selection and skill sets near the top of the list," said James Brehm, Founder and Technology Evangelist, James Brehm & Associates, LLC. "Our team is currently conducting a comprehensive study of the IoT platform market, and two of the early themes we're finding is that the most successful IoT platform companies (1) aren't just software based tools, rather they include a team to assist with development and integration and (2) are ones most people have never heard of. Boot strapped and cash flow positive with national and international clients, Bright Wolf has an open standards-based platform designed for change and longevity and decades of connected systems experience to lead the integration process that most platform companies lack. The fact that Haemonetics, a Massachusetts based company, selected Bright Wolf for this complex and regulation heavy implementation should not be lost on anyone.”
For more information on Bright Wolf, please visit: http://www.bright-wolf.com or contact David Houghton: 919.937.2575 | david(at)bright-wolf(dot)com
About Bright Wolf
Bright Wolf, founded in 2009, enables solutions that transform people, processes and products through the Internet of Things. Bright Wolf’s purpose built platform, shaped by decades of connected systems experience and augmented by our full spectrum application development, operations and support services, accelerates development and deployment of secure, industrial strength, future-resistant systems, allowing companies to harness innovative IoT solutions.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com
About James Brehm Associates
James Brehm & Associates is a leading consulting and market intelligence firm providing project-based and strategic advisory services, focused solely on the rapidly emerging Internet of Things (IoT) space. With connected technology poised to change the world, our aim is to provide pragmatic, measurable, and practicable direction for customers who want to transform their businesses or their customers businesses. For more information, please visit: http://www.jbrehm.com